Product Images Carvedilol Phosphate
View Photos of Packaging, Labels & Appearance
- 10 - 10mg
- 20 - 20mg
- 40 - 40mg
- 80 - 80mg
- Chemical Structure - carvedilol phosphate extended release capsules 1
- Figure 1 Survival Analysis for COPERNICUS (Intent-to-Treat) - carvedilol phosphate extended release capsules 2
- Figure 2 Effects on Mortality for Subgroups in COPERNICUS - carvedilol phosphate extended release capsules 3
- Figure 3 Survival Analysis for CAPRICORN (Intent-to-Treat) - carvedilol phosphate extended release capsules 4
- Figure 4 Effects on Mortality for Subgroups in CAPRICORN - carvedilol phosphate extended release capsules 5
- Figure 5. Changes from Baseline in Systolic Blood Pressure and Diastolic Blood Pressure Measured by 24-Hour ABPM - carvedilol phosphate extended release capsules 6
Product Label Images
The following 10 images provide visual information about the product associated with Carvedilol Phosphate NDC 42291-480 by Avkare, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
10 - 10mg
This text provides information about a medication with the NDC code 42291-479-30, which is an extended-release capsule containing 10 mg of Carvedilol. It includes details on usage instructions, storage precautions, and contact information for inquiries. The product is manufactured by AKARE and is stated to have a revision date of 07-2023.*
20 - 20mg
This is a prescription label providing information about Carvedilol Phosphate Extended-Release Capsules. The document includes details such as the prescription number, dosage, safety warnings, and additional information for medical professionals. It also specifies the quantity of capsules and storage instructions.*
40 - 40mg
The text describes a medication named Carvedilol Phosphate, with each extended-release capsule containing 40g of the active ingredient. It provides dosing instructions, storage conditions, and precautions like not using capsules with a broken safety seal. The medication is distributed by AVKARE and includes contact information in case of accidental overdose.*
80 - 80mg
Each extended-release capsule contains 80 mg of carvedilol phosphate. This medication is in capsule form and should not be used if the printed safety seal under the cap is broken or missing. It is essential to keep this medication out of the reach of children. In case of accidental overdose, seek professional help or contact a poison control center immediately. The prescription is for 30 capsules manufactured by Akorn.*
Chemical Structure - carvedilol phosphate extended release capsules 1
Figure 1 Survival Analysis for COPERNICUS (Intent-to-Treat) - carvedilol phosphate extended release capsules 2
This text provides information related to mortality rates associated with the drug Carvedilol over a period of 9, 12, 15 and 18 months, with a corresponding P-value of 0.0014.*
Figure 2 Effects on Mortality for Subgroups in COPERNICUS - carvedilol phosphate extended release capsules 3
This text appears to be a table outlining different characteristics of patients, such as gender, age groups, race, medical conditions, and medication usage. The table seems to present information on heart rate, systolic blood pressure, and the use of spironolactone medication. The numbers at the bottom may represent statistical values or categories related to the patients.*
Figure 3 Survival Analysis for CAPRICORN (Intent-to-Treat) - carvedilol phosphate extended release capsules 4
Figure 4 Effects on Mortality for Subgroups in CAPRICORN - carvedilol phosphate extended release capsules 5
This text appears to be a table or a list outlining various factors and variables related to a study or evaluation post Myocardial Infarction (MI). The information includes age, gender, randomization timing post-MI, prior medication, Killip classification, thrombolytic treatment, Percutaneous Transluminal Coronary Angioplasty (PTCA) for MI, Hazard Ratios, history of Congestive Heart Failure (CHF), diuretic usage during MI, presence/absence of angina, hypertension, diabetes, heart rate, and blood pressure. The data seems to be grouped for analysis purposes.*
Figure 5. Changes from Baseline in Systolic Blood Pressure and Diastolic Blood Pressure Measured by 24-Hour ABPM - carvedilol phosphate extended release capsules 6
This is a description of different doses of extended-release carvedilol phosphate capsules and their effects on systolic blood pressure (SBP) and diastolic blood pressure (DBP) over time after morning dose. The text also mentions the use of locally weighted regression smoothing methodology for data analysis.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
